Document Library

Filter by country
Africa
Angola
Benin
Burkina Faso
Burundi
Cameroon
Central African Republic (the)
Chad
Comoros (the)
Congo (the)
Cote d'Ivoire
Congo, DR
Eritrea
Ethiopia
The Gambia
Ghana
Guinea-Bissau
Guinea
Kenya
Lesotho
Liberia
Madagascar
Malawi
Mali
Mauritania
Mozambique
Niger
Nigeria
Rwanda
Sao Tome and Principe
Senegal
Sierra Leone
South Sudan
Tanzania, UR
Togo
Uganda
Zambia
Zimbabwe
South-East Asia
Bangladesh
Bhutan
Korea, DPR
India
Myanmar
Nepal
Sri Lanka
Timor Leste
Americas
Cuba
Haiti
Honduras
Nicaragua
Bolivia
Guyana
Europe
Albania
Armenia
Azerbaijan
Bosnia-Herzegovina
Georgia
Kyrgyzstan
Moldova
Tajikistan
Turkmenistan
Ukraine
Uzbekistan
Western Pacific
Cambodia
China
Indonesia
Kiribati
Lao PDR
Mongolia
Papua New Guinea
Solomon Islands
Vietnam
Eastern Mediterranean
Afghanistan
Djibouti
Pakistan
Somalia
Sudan (the)
Yemen

Gavi HSIS policy

Dr Rana Hajjeh

Early market shaping roadmap: novel tuberculosis vaccines: public summary 2026

Tuberculosis (TB) is the world’s leading cause of death from an infectious agent, with 10.7 million cases and 1.2 million deaths in 2024, predominantly in low- and middle-income countries (LICs and MICs). The World Health Organization (WHO) WHO Preferred Product Characteristics (PPC) for New Tuberculosis Vaccines prioritises development of vaccines to prevent pulmonary TB disease in adolescents and adults. This document is the public summary of the early market shaping roadmap for novel TB vaccines.

Code of Ethics and Conduct for Governance Officials

The Code defines the ethical principles and behavioural standards expected of all Governance Officials and guides decision‑making aligned with Gavi’s mission and values. It promotes transparency, accountability and respectful collaboration across governance roles by setting clear expectations for conduct.

Gavi equity playbook

Gavi equity playbook